Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Bio Rad Laboratories Inc Stock Research

BIO

364.42USD+4.05(+1.12%)Market Closed
Watchlist

Market Summary

USD364.42+4.05
Market Closed
1.12%

BIO Alerts

  • Losses in recent quarter

BIO Stock Price

BIO RSI Chart

BIO Valuation

Market Cap

10.7B

Price/Earnings (Trailing)

-24.97

Price/Sales (Trailing)

3.86

EV/EBITDA

-21.56

Price/Free Cashflow

69.42

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-8.94%

Return on Equity

-1.96%

Return on Assets

-1.4%

Free Cashflow Yield

1.44%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.8B

Revenue Y/Y

-1.45%

Revenue Q/Q

0.64%

BIO Earnings

Earnings (TTM)

-428.4M

Earnings Y/Y

-25.63%

Earnings Q/Q

-1.8K%

Price Action

52 Week Range

344.63509.62
(Low)(High)

Last 7 days

-1.1%

Last 30 days

-4.1%

Last 90 days

-0.1%

Trailing 12 Months

-16.7%

BIO Financial Health

Current Ratio

5.56

Debt/Equity

0.12

Debt/Cashflow

0.2

BIO Investor Care

Buy Backs (1Y)

1.47%

Diluted EPS (TTM)

-6.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Which funds bought or sold BIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
added
42.25
4,281
38,291
0.01%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
-1,199
4,549
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-59,940
227,472
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-5,200,720
-
-%
2023-08-21
BOKF, NA
reduced
-27.27
-2,236
3,033
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
379
379
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-0.49
-3,116,000
11,550,000
0.11%
2023-08-21
OSAIC HOLDINGS, INC.
unchanged
-
-4,900
18,803
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-0.2
-1,597,040
6,187,280
0.01%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.47
-4,045,210
13,095,600
0.02%

1–10 of 47

Latest Funds Activity

Are funds buying BIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIO
No. of Funds

Schedule 13G FIlings of Bio Rad Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.66%
2,391,436
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
1,582,313
SC 13G/A
Apr 11, 2022
schwartz alice n
89.7%
4,555,452
SC 13D/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 09, 2022
vanguard group inc
9.21%
2,287,465
SC 13G/A
Feb 01, 2022
blackrock inc.
7.1%
1,768,081
SC 13G/A
Feb 10, 2021
vanguard group inc
9.18%
2,272,373
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G
Jan 29, 2021
blackrock inc.
7.6%
1,892,336
SC 13G/A

Recent SEC filings of Bio Rad Laboratories

View All Filings
Date Filed Form Type Document
Sep 14, 2023
3
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading

Peers (Alternatives to Bio Rad Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.0B
7.0B
-5.38% -12.23%
29.09
4.71
5.03% -14.68%
24.7B
4.0B
-3.30% -3.12%
27.83
6.25
2.30% 16.37%
21.9B
4.5B
-17.36% -28.94%
-5.22
4.9
-4.92% -21931.58%
16.2B
3.0B
2.60% -2.79%
23.99
5.41
3.16% -3.93%
16.1B
2.8B
-15.95% -22.45%
19.74
5.69
-24.31% 21.35%
MID-CAP
SMALL-CAP
2.4B
146.1M
-8.89% 61.75%
-7.4
16.16
4.72% -55.19%
960.9M
112.0M
5.18% 169.83%
-14.6
8.58
0.83% 16.42%
749.3M
189.6M
-19.57% -31.57%
-3.92
3.95
18.74% 17.75%
175.0M
114.1M
-1.44% 44.37%
-32.24
1.53
-5.49% -48.58%
118.7M
99.2M
-1.73% -74.89%
-2.09
1.2
-26.56% -199.52%
99.7M
31.5M
-1.32% 40.85%
-0.68
3.16
35.12% -38.47%
73.7M
143.9M
-41.73% -89.43%
-0.44
0.51
0.71% -18.99%
72.1M
52.7M
-20.39% -41.08%
-9.55
1.37
2.10% -1984.29%
64.0M
67.1M
-25.42% -59.63%
-0.58
0.95
-12.13% -17.68%

Bio Rad Laboratories News

MarketBeat
ProShare Advisors LLC Grows Holdings in Bio-Rad Laboratories ....
MarketBeat,
71 minutes ago
Digital Journal

Returns for BIO

Cumulative Returns on BIO

12.2%


10-Year Cumulative Returns

12.4%


7-Year Cumulative Returns

4.1%


5-Year Cumulative Returns

-10.8%


3-Year Cumulative Returns

Risks for BIO

What is the probability of a big loss on BIO?

68.8%


Probability that Bio Rad Laboratories stock will be more than 20% underwater in next one year

43.9%


Probability that Bio Rad Laboratories stock will be more than 30% underwater in next one year.

16.1%


Probability that Bio Rad Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio Rad Laboratories was unfortunately bought at previous high price.

Drawdowns

Financials for Bio Rad Laboratories

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.4%2,7692,7792,8022,8052,8712,8962,9232,9802,8802,7012,5462,3802,2942,3292,3122,3042,2892,2922,2892,2942,283
Gross Profit-2.1%1,4951,5271,5671,5701,6341,6401,6381,6981,6291,5211,4381,3081,2481,2631,2571,2591,2391,2331,2231,2361,248
  S&GA Expenses0.0%855855828837842848877873855831799795799811825824824833835823820
  R&D Expenses0.3%267267257253247246261259254242218218206204203199200197199222235
EBITDA100.0%--202-4,666-7,803-2,594-2245,4408,5615,2285,4645,0714,6932,6732,1972,4266851,3719426781,7551,444
EBITDA Margin100.0%--0.07*-1.67*-2.78*--0.08*1.86*2.87*1.82*2.02*1.99*1.97*1.17*0.94*1.05*0.30*0.60*0.41*0.30*0.77*0.63*
Interest Expenses3.5%48.0046.0038.0027.0016.005.002.006.0011.0017.0022.0023.0023.0023.0023.0023.0024.0024.0024.0024.0023.00
Earnings Before Taxes-114.0%-526-245-4,704-7,824-2,593-2165,4498,5655,2275,3174,9184,5292,5092,0332,2615201,2067765131,6001,280
EBT Margin100.0%--0.09*-1.68*-2.79*--0.08*1.86*2.87*1.81*1.96*1.93*1.90*1.09*0.87*0.98*0.23*0.53*0.34*0.22*0.69*0.56*
Net Income-124.0%-428-191-3,627-6,027-1,935-93.154,2546,6664,0514,1003,8063,5211,9471,5791,7593779055743661,2771,030
Net Income Margin100.0%--0.07*-1.29*-2.15*--0.03*1.45*2.23*1.40*1.52*1.50*1.48*0.85*0.68*0.76*0.16*0.40*0.25*0.16*0.56*0.45*
Free Cashflow-100.0%-12782.00152364459536667586529476369322381359272244162156148116
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-12.4%11,97813,66713,50212,05812,68214,37417,79919,95315,11813,93312,97312,02110,0978,6848,0097,1777,6476,8635,6116,7196,386
  Current Assets-4.2%3,1393,2773,1583,1403,2503,3031,9902,4662,2892,1752,1402,3242,1332,0832,1802,0482,0882,0322,0232,0341,992
    Cash Equivalents-16.0%390464434518597802471860733673662840608604663561581456434435403
  Inventory3.1%777753719686657605572589599605622640628557554588590590584601591
  Net PPE---499---512---491--486499496499503509484490
  Goodwill0.9%412408406400347346347292292292292292292264264264235231220502500
Liabilities-9.5%3,5313,9043,8863,6053,7604,1914,1144,6213,5233,3243,0933,1962,7442,3912,2542,0462,1601,9991,5911,8181,747
  Current Liabilities-1.3%582590569571614648681650587610632987927869905434446444451453442
  Long Term Debt---1,198---11.00---12.00---14.00---439439439
    LT Debt, Non Current0.0%1,1981,1981,1981,1971,1971,19711.0011.0011.0011.0012.0012.0012.0012.0014.00438438438439--
Shareholder's Equity-13.5%8,4479,7649,6158,4548,94510,20313,68515,33211,59510,6099,8908,8257,3536,2935,7575,1315,4874,8644,0204,9004,639
  Retained Earnings-11.7%8,8059,9679,8989,0479,21010,13813,52515,08111,15910,2459,2688,4297,1236,1575,4714,9175,1854,5863,7224,5514,281
  Additional Paid-In Capital2.3%474463447431472459442421460445429412429424410396411403394382377
Accumulated Depreciation---1,009---1,002---961--876883851850828818812799
Shares Outstanding-0.8%29.0030.00-30.0030.0030.00-30.0030.0030.00-30.0030.0030.00-30.0030.0030.00-30.0030.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations18.5%287242194275505606669793698636585450414478458403366288286250216
  Share Based Compensation------------43.0036.00--36.0033.00----
Cashflow From Investing47.7%-189-361-1,207-1,705-1,709-1,665-797-289-117-105-69.89-71.34-272-198-208-202-122-190-186-145-130
Cashflow From Financing-38.3%-293-2129741,0651,0581,182-55.43-481-465-471-523-105-110-123-22.76-64.98-62.66-49.03-48.682.001.00
  Buy Backs-181-216125125-50.0050.0050.0050.0010010811312828.0069.0064.0049.0049.00-2.00

BIO Income Statement

2023-06-30
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net sales$ 681,110$ 691,099$ 1,357,954$ 1,391,161
Cost of goods sold318,627296,068633,054593,495
Gross profit362,483395,031724,900797,666
Selling, general and administrative expense207,824207,793433,377404,485
Research and Development Expense65,04264,346139,993123,881
Segment profit (loss)89,617122,892151,530269,300
Interest expense12,34310,72024,68014,768
Foreign exchange (gains) losses, net(1,253)897(3,600)(1,231)
Marketable Securities, Unrealized (Gain) Loss1,595,4421,338,1901,612,9675,883,307
Other Nonoperating Income (Expense)16,4886,71066,91939,307
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest(1,500,427)(1,220,205)(1,415,598)(5,588,237)
(Provision) benefit for income taxes338,176295,091322,3091,295,776
Net income attributable to Bio-Rad$ (1,162,251)$ (925,114)$ (1,093,289)$ (4,292,461)
Basic earnings per share:    
Net income per share basic attributable to Bio-Rad$ (39.59)$ (31.05)$ (37.09)$ (143.74)
Weighted average common shares - basic29,35529,79429,47529,863
Diluted earnings per share:    
Weighted average common shares - diluted29,35529,79429,47529,863

BIO Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
ASSETS:  
Cash and cash equivalents$ 390,001$ 434,215
Short-term investments1,332,6851,356,457
Restricted investments5,5605,560
Accounts receivable, net491,575494,645
Inventory776,600719,316
Prepaid expenses122,641124,179
Other current assets19,80423,604
Total current assets3,138,8663,157,976
Property, plant, and equipment1,575,0751,508,020
Less: accumulated depreciation and amortization1,061,0621,009,408
Property, plant and equipment, net514,013498,612
Operating lease right-of-use assets173,922180,952
Goodwill, net411,519406,488
Purchased intangibles, net328,710332,147
Other investments7,311,1358,830,892
Other assets100,06494,599
Assets11,978,22913,501,666
LIABILITIES AND STOCKHOLDERS' EQUITY:  
Accounts payable149,535135,041
Accrued payroll and employee benefits154,704194,790
Current maturities of long-term debt and notes payable476465
Income and other taxes payable74,48132,428
Current operating lease liabilities36,54336,336
Other current liabilities166,243169,648
Total current liabilities581,982568,708
Long-term debt, net of current maturities1,198,3841,197,716
Deferred income taxes1,401,8271,770,481
Operating lease liabilities146,849153,597
Other long-term liabilities202,294195,912
Total liabilities3,531,3363,886,414
Stockholders' equity:  
Additional paid-in capital473,872447,454
Retained earnings8,804,6649,898,203
Accumulated other comprehensive loss(372,862)(466,822)
Total stockholders' equity8,446,8939,615,252
Total liabilities and stockholders' equity11,978,22913,501,666
Common Class A [Member]  
Stockholders' equity:  
Common stock22
Common Class B [Member]  
Stockholders' equity:  
Common stock11
Treasury Class A [Member]  
Stockholders' equity:  
Treasury stock$ (458,784)$ (263,586)
Treasury Stock, Common  
Stockholders' equity:  
Treasury Stock, Shares1,160,074640,492
Norman D. Schwartz
7900
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.